Why Pfizer Stock Popped Today
Key Points
RBC upgraded Pfizer stock today, removing its sell rating on the big pharma giant.
Pfizer stock is down 11% from its highs, and pays a 6.7% dividend yield.
- 10 stocks we like better than Pfizer ›
Pfizer (NYSE: PFE) shares gained 2.8% through 11:15 a.m. ET Thursday, and investors can thank the friendly bankers at RBC Capital Markets for that.
This morning, RBC removed its sell rating from Pfizer stock, upgrading the shares from "underperform" to "sector perform."
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Why RBC likes, not loves, Pfizer stock
So RBC isn't telling you to buy Pfizer stock... yet. But the banker is saying there's no longer a need to sell the big pharma giant. Why is that?
Basically, because RBC thinks the price is right on Pfizer shares after retreating 11% from their highs. RBC notes that investors have been cautious about Pfizer of late, worried that the company is lagging in the race to bring GLP-1 weight-loss drugs to market and at risk of revenue decline.
RBC isn't optimistic about Pfizer's chances of breaking Eli Lilly's (NYSE: LLY) and Novo Nordisk's (NYSE: NVO) stranglehold on the GLP-1 market. But balancing this risk is a pair of late-stage clinical trial cancer drugs Pfizer wants to bring to market: sigvotatug vedotin for treating lung cancer, and mevro for treating metastatic castration-resistant prostate cancer. RBC thinks success with these two drugs could add $1.2 billion and $2.7 billion, respectively, to Pfizer's revenue stream.
What's next for Pfizer stock
Near-term, Pfizer stock is still expected to struggle, with most analysts forecasting single-digit revenue declines this year and next -- and even steeper earnings declines.
That's not great news, but here's the thing: Even assuming earnings decline as forecast, to $3 a share or so, Pfizer stock only costs about nine times earnings. With a 6.7% dividend yield, Pfizer doesn't need to grow much at all, or soon at all, to justify its share price today.
At today's valuation, Pfizer is simply too cheap to sell.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 11, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
